Literature DB >> 14504511

Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.

Dietmar Ulrich1, Klaus Hrynyschyn, Norbert Pallua.   

Abstract

Dupuytren's contracture is a fibroproliferative disorder characterized by progressive deposition of mature collagen fibers. In other fibrotic diseases affecting organs such as the liver, lung, heart, and skin, matrix metalloproteinases (MMPs) and their natural inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), play an important role. In this study, serum concentrations of MMP-1, MMP-2, MMP-9, TIMP-1, and TIMP-2 were determined in 22 patients (five women and 17 men; average age, 67 +/- 11 years) with Dupuytren's disease using an enzyme-linked immunosorbent assay. Tissue samples were obtained for standard histological and immunohistochemical analyses. Sera and samples of palmar fascia from 20 patients (13 women and seven men; average age, 60 +/- 15 years) who had undergone hand surgery for carpal tunnel syndrome were used as the control group. Statistical analysis was performed using the Mann-Whitney test. Patients with Dupuytren's contracture presented with a TIMP-1 concentration of 437 +/- 160 ng/ml, a significantly higher TIMP-1 concentration than that seen in the control patients, who had a concentration of 321 +/- 70 ng/ml (p < 0.05). Patients with a proliferative active disease (n = 14) had a significantly higher TIMP-1 concentration (525 +/- 136 ng/ml) than patients (n = 8) with a contracture in the late involutional and residual phase (286 +/- 41 ng/ml; p < 0.05). There were no significant differences in the TIMP-2, MMP-1, MMP-2, and MMP-9 serum concentrations between patients with palmar fibromatosis and the control group. Patients with Dupuytren's disease had a significantly lower MMP-to-TIMP ratio (1.1 +/- 0.3; p < 0.05) than the control group (1.5 +/- 0.35). Patients with an active palmar fibromatosis presented a significantly (p < 0.05) reduced ratio (1 +/- 0.2) compared with those in later phases (1.4 +/- 0.3). TIMP-1 and TIMP-2 could be detected in tissue of patients with Dupuytren's contracture, with an accumulation in proliferative areas. MMPs could be detected locally in Dupuytren's tissue in a few patients, with less positive staining than for TIMPs. In the control group, there was just little or no staining for TIMPs and MMPs. The data indicate that the physiological balance between MMPs and their natural inhibitors is disturbed in patients with a proliferative active Dupuytren's disease. The decrease in the systemic MMP-to-TIMP ratio can cause increased synthesis and deposition of collagen, leading to palmar fibromatosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14504511     DOI: 10.1097/01.PRS.0000081462.40448.49

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  10 in total

1.  Update on the role of molecular factors and fibroblasts in the pathogenesis of Dupuytren's disease.

Authors:  Massimiliano Tripoli; Adriana Cordova; Francesco Moschella
Journal:  J Cell Commun Signal       Date:  2016-06-07       Impact factor: 5.782

Review 2.  Scientific understanding and clinical management of Dupuytren disease.

Authors:  Barbara Shih; Ardeshir Bayat
Journal:  Nat Rev Rheumatol       Date:  2010-11-09       Impact factor: 20.543

3.  Identification of potential matrix metalloproteinase-2 inhibitors from natural products through advanced machine learning-based cheminformatics approaches.

Authors:  Ruoqi Yang; Guiping Zhao; Bin Cheng; Bin Yan
Journal:  Mol Divers       Date:  2022-06-30       Impact factor: 2.943

4.  Molecular mechanisms and treatment strategies for Dupuytren's disease.

Authors:  David B O'Gorman; Linda Vi; Bing Siang Gan
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423

5.  Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration.

Authors:  Ralf Smeets; Dietmar Ulrich; Frank Unglaub; Michael Wöltje; Norbert Pallua
Journal:  Int Wound J       Date:  2008-06       Impact factor: 3.315

6.  The Rationale for Treating the Nodule in Dupuytren's Disease.

Authors:  Lynn D Ketchum
Journal:  Plast Reconstr Surg Glob Open       Date:  2015-01-08

7.  Impact of leg lengthening on viscoelastic properties of the deep fascia.

Authors:  Hai-Qiang Wang; Yi-Yong Wei; Zi-Xiang Wu; Zhuo-Jing Luo
Journal:  BMC Musculoskelet Disord       Date:  2009-08-21       Impact factor: 2.362

Review 8.  Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics.

Authors:  Björn Pasternak; Per Aspenberg
Journal:  Acta Orthop       Date:  2009-12       Impact factor: 3.717

9.  Elevated plasma levels of TIMP-1 in patients with rotator cuff tear.

Authors:  Hanna C Björnsson Hallgren; Pernilla Eliasson; Per Aspenberg; Lars E Adolfsson
Journal:  Acta Orthop       Date:  2012-10-08       Impact factor: 3.717

10.  Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytren's Contracture.

Authors:  Latha Satish; William A LaFramboise; David B O'Gorman; Sandra Johnson; Benjamin Janto; Bing Siang Gan; Mark E Baratz; Fen Z Hu; J Christopher Post; Garth D Ehrlich; Sandeep Kathju
Journal:  BMC Med Genomics       Date:  2008-04-23       Impact factor: 3.063

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.